Li Y, Yu H, Feng J
Front Immunol. 2023; 14:1085154.
PMID: 36865551
PMC: 9971601.
DOI: 10.3389/fimmu.2023.1085154.
Tong J, Jiang W, Zhang X, Wang R, Qiao T, Song Y
J Int Med Res. 2022; 50(12):3000605221139555.
PMID: 36495170
PMC: 9747877.
DOI: 10.1177/03000605221139555.
Wang L, Zhang S, Wang X
Front Oncol. 2021; 10:602416.
PMID: 33489906
PMC: 7817624.
DOI: 10.3389/fonc.2020.602416.
Li X, Rosenkrans Z, Wang J, Cai W
Am J Transl Res. 2020; 12(5):1491-1514.
PMID: 32509158
PMC: 7270023.
Xie H, Shao Z, Li D
Chin J Cancer. 2017; 36(1):36.
PMID: 28356139
PMC: 5372254.
DOI: 10.1186/s40880-017-0202-y.
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.
Buque A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman W
Oncoimmunology. 2016; 5(6):e1149674.
PMID: 27471617
PMC: 4938376.
DOI: 10.1080/2162402X.2016.1149674.
Role of Conserved Disulfide Bridges and Aromatic Residues in Extracellular Loop 2 of Chemokine Receptor CCR8 for Chemokine and Small Molecule Binding.
Barington L, Rummel P, Luckmann M, Pihl H, Larsen O, Daugvilaite V
J Biol Chem. 2016; 291(31):16208-20.
PMID: 27226537
PMC: 4965569.
DOI: 10.1074/jbc.M115.706747.
Symmetrical bis-tertiary amines as novel CXCR4 inhibitors.
Bai R, Liang Z, Yoon Y, Liu S, Gaines T, Oum Y
Eur J Med Chem. 2016; 118:340-50.
PMID: 27179215
PMC: 4894032.
DOI: 10.1016/j.ejmech.2016.04.040.
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
Xu H, Lu H, Xu Z, Luan L, Li C, Xu Y
ACS Med Chem Lett. 2016; 7(4):397-402.
PMID: 27096048
PMC: 4834652.
DOI: 10.1021/acsmedchemlett.5b00489.
Synthesis of pyridine derivatives as potential antagonists of chemokine receptor type 4.
Mooring S, Gaines T, Liang Z, Shim H
Heterocycl Comm. 2015; 20(3):149-153.
PMID: 25620839
PMC: 4300533.
DOI: 10.1515/hc-2014-0041.
Quantitative structure activities relationships of some 2-mercaptoimidazoles as CCR2 inhibitors using genetic algorithm-artificial neural networks.
Saghaie L, Shahlaei M, Fassihi A
Res Pharm Sci. 2013; 8(2):97-112.
PMID: 24019819
PMC: 3764681.
Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.
Rummel P, Arfelt K, Baumann L, Jenkins T, Thiele S, Luttichau H
Br J Pharmacol. 2012; 167(6):1206-17.
PMID: 22708643
PMC: 3504988.
DOI: 10.1111/j.1476-5381.2012.02076.x.
3D-QSAR studies on CCR2B receptor antagonists: Insight into the structural requirements of (R)-3-aminopyrrolidine series of molecules based on CoMFA/CoMSIA models.
Gade S, Mahmood S
J Pharm Bioallied Sci. 2012; 4(2):123-33.
PMID: 22557923
PMC: 3341716.
DOI: 10.4103/0975-7406.94813.
C6-C8 bridged epothilones: consequences of installing a conformational lock at the edge of the macrocycle.
Zhan W, Jiang Y, Sharma S, Brodie P, Bane S, Kingston D
Chemistry. 2011; 17(52):14792-804.
PMID: 22127984
PMC: 3248799.
DOI: 10.1002/chem.201102630.
Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2.
Jensen P, Thiele S, Steen A, Elder A, Kolbeck R, Ghosh S
Br J Pharmacol. 2011; 166(1):258-75.
PMID: 22050085
PMC: 3415653.
DOI: 10.1111/j.1476-5381.2011.01771.x.
Regio- and stereoselective syntheses of the natural product CCR5 antagonist anibamine and its three olefin isomers.
Zhang F, Zaidi S, Haney K, Kellogg G, Zhang Y
J Org Chem. 2011; 76(19):7945-52.
PMID: 21875065
PMC: 3197777.
DOI: 10.1021/jo2013669.
A digest on the role of the tumor microenvironment in gastrointestinal cancers.
Augsten M, Hagglof C, Pena C, Ostman A
Cancer Microenviron. 2011; 3(1):167-76.
PMID: 21209782
PMC: 2990496.
DOI: 10.1007/s12307-010-0040-9.
Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.
Nishizawa R, Nishiyama T, Hisaichi K, Hirai K, Habashita H, Takaoka Y
Bioorg Med Chem. 2010; 18(14):5208-23.
PMID: 20542438
PMC: 7566811.
DOI: 10.1016/j.bmc.2010.05.057.
Chemokines and their receptors in the allergic airway inflammatory process.
Velazquez J, Teran L
Clin Rev Allergy Immunol. 2010; 41(1):76-88.
PMID: 20352527
DOI: 10.1007/s12016-010-8202-6.
Therapeutic targeting of chemokine interactions in atherosclerosis.
Koenen R, Weber C
Nat Rev Drug Discov. 2010; 9(2):141-53.
PMID: 20118962
DOI: 10.1038/nrd3048.